Swedish Cardiac And Renal Failure Study-1

Previous studies have shown that patients with heart failure with reduced pumping function and preserved kidney function experience improved symptoms, longer survival, and fewer hospitalizations when treated with medications such as eplerenone. However, individuals with impaired kidney function have been excluded from these trials due to concerns about potential adverse effects on potassium levels, kidney function, and possibly also blood pressure. As a result, clear treatment recommendations for this high-risk group are lacking. In recent years, however, background therapies have been modern

Trial Details

NCT ID
NCT07029503
Phase
PHASE2
Sponsor
Karolinska Institutet
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Eplerenone
Locations (sample)
  • Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • The participant has given their written consent to participate
  • A diagnosis of HFrEF according to current criteria, for at least three months before the screening visit
  • Echocardiography within 24 months of the screening visit with ejection fraction ≤ 40%. The responsible investigator is allowed to order a new TTE a…
  • New York Heart Association class II-III

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →